FEMY — FEMASYS INC

Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1339005 ·
Last close
$2.98
Market Cap
$24.96M
52W High
$10.56
52W Low
$2.02
ADV30
1,418,507
Next earnings
Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal patency; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; and FemCath, a cornual balloon catheter for selective tube evaluation. It also provides FemBloc, a non-surgical female permanent birth control solution. The company offers its products to gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 424,889 266,283 -4,223,533 846,100 16,495,245 5,386,041 9,205,352
Dec 2025 813,387 510,262 -4,622,728 -3,950,305 20,724,177 9,266,353 14,854,875
Sep 2025 729,394 435,556 -3,653,768 -4,194,821 16,290,153 4,569,038 11,733,902
Jun 2025 409,268 251,097 -3,851,566 -4,585,922 13,780,409 3,218,067 12,272,974

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-18,068,859
Investing CF
$-612,631
Financing CF
$20,247,323
CapEx
$-612,631
Dividends Paid
Buybacks
EPS Diluted TTM
$-9.80
As of
2026-08-16

Balance + Analyst (yfinance extras)

Retained Earnings
$-144,980,044
Inventory
$6,105,267
Receivables
$172,264
ST Investments
EBIT TTM
$-10,271,186
Pretax Income TTM
$-11,879,463
Interest Exp TTM
$1,608,277
Analysts
3

Yahoo Snapshot (yfinance, live)

Total Revenue
$2,299,497
EBITDA
$-17,229,926
Free Cash Flow
$-11,230,021
Enterprise Value
$28,136,822
Total Cash
$1,443,502
Total Debt
$4,790,245
Shares Out
8,375,027
Trailing EPS
$-2.72
Book Value
$1.33
ROE
-425.0%
ROA
-84.2%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 2,293,313 -17,588,669 -18,627,887 20,724,177 14,854,875 -18,690,565
Dec 2024 1,629,108 -17,785,805 -18,816,628 12,445,002 10,140,580 -19,444,009
Dec 2023 1,071,970 -14,508,415 -14,247,124 27,755,825 9,403,236 -11,280,546
Dec 2022 1,206,218 -11,600,264 -11,394,170 16,895,570 1,653,051 -10,731,973

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-2.12

Peers — same industry

TickerNameMarket CapLastDaily %
GTHP GUIDED THERAPEUTICS INC $24.13M $0.25
RDGL VIVOS INC $25.95M $0.05
PSTV CERENOME, INC. $26.42M $3.84
PETV PetVivo Holdings, Inc. $26.47M $0.70
HRGN Harvard Apparatus Regenerative Technology, Inc. $26.71M $1.52

News headlines (Yahoo Finance, 1h cache)

Femasys Secures FDA Pathway for Non-Surgical Contraceptive
2026-08-19 17:36 · Yahoo
FEMY Stock Rallies On Key Regulatory Milestone For Investigational Birth Control Technology – Retail Sees 500% Upside Potential
2026-08-19 16:01 · Yahoo
Femasys Secures FDA Approval for Modular PMA Pathway for FemBloc
2026-08-19 14:37 · Yahoo
Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc®
2026-08-19 13:00 · Yahoo
Femasys Strengthens and Extends Global Patent Protection for FemBloc® with First Issued Blended Polymer Patents
2026-08-12 13:00 · Yahoo
Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million
2026-08-07 13:25 · Yahoo
Femasys Regains Compliance with Nasdaq Listing Requirements
2026-06-24 13:00 · Yahoo
Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter
2026-05-13 13:00 · Yahoo
Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update
2026-05-08 20:05 · Yahoo
Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete
2026-05-05 13:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.